Fairvalue-Calculator Fairvalue-Calculator
EN DE

Aytu BioPharma, Inc (AYTU) Fair Value & Analysis

Healthcare · US · Market cap $22.6M

Price$2.19
Fair Value$1.18
Upside-46.1%
Quality95/100
Evidence: Low Range $0.8800 – $1.77

Fair value as of: Jun 25, 2026

Analysis

Aytu BioPharma, Inc (AYTU) currently trades at $2.19, while our model-based Fair Value estimate is $1.18 — implying the stock looks roughly 46.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children wi…

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1827% Jiangsu Hengrui Pharmaceuticals Co (600276) -43% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -24% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -81%

Frequently asked questions

Is Aytu BioPharma, Inc (AYTU) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $1.18 versus a price of $2.19 — about −46% (overvalued). Model-based estimate, not financial advice.
What is the fair value of AYTU?
Our 21-model fair value for Aytu BioPharma, Inc is $1.18 (as of Jun 25, 2026), built from audited fundamentals. The current price is $2.19.
What is the quality score of AYTU?
Aytu BioPharma, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.